皮拉醇具有多方面的抗炎作用,向前列腺素E,循环氧化酶和白细胞的氧化突发
Sónia Rocha1, Jorge Silva1, Vera L M Silva2
1LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto 4050-313, Portugal.
概括
研究人员探索了28种pyrazole衍生物的抗炎作用潜力. 关键发现确定了特定的结构特征,如4-基和替代,对于降低前列腺素E2 (PGE2) 水平和抑制炎症至关重要.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 增加的前列腺素E2 (PGE2) 水平与各种疾病有关.
- 目前的非特异性环氧激酶抑制剂会引起副作用.
- 有针对性的PGE2抑制为炎症性疾病提供了治疗策略.
研究的目的:
- 系统地分析28种pyrazole衍生物,以发现它们降低PGE2水平的潜力.
- 探索针对性抗炎药物开发的新机制.
- 为了确定pyrazole衍生物的结构-活性关系.
主要方法:
- 在人体全血中PGE2降低的体外评估.
- 对循环氧化酶-1 (COX-1) 和循环氧化酶-2 (COX-2) 酶抑制的测定.
- 对人类白细胞中COX-2表达调节和氧化突发抑制的评估.
主要成果:
- 发现了显著的结构-活性关系,突出显示了4- styryl 组和替代物的重要性.
- 皮拉8降低了COX-2的表达,以减少PGE2.
- 皮拉-1,2,3-三-18具有双重活性:抑制氧化突发和COX-2.
- 皮拉26选择性地抑制了COX-1以有效降低PGE2.
结论:
- 皮拉衍生物具有多方面的抗炎功能.
- 特定的结构特征增强了抗炎活性.
- 这些发现为开发基于皮拉的新型抗炎药物提供了洞察力.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
276
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
276
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
408
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
408
Drugs for Treatment of Ulcerative Colitis in IBD
135
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
380
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
380
Gastritis-II: Pathophysiology
319
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
319
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167


